Here, we summarize the most relevant findings that extend our current understanding of RECK as a regulator of inflammation and fibrosis, and its induction as a potential strategy to blunt the development and progression of NASH and HCC. This evidence concerns the gene RECK and metabolic dysfunction-associated steatohepatitis.